Evidence map›Paper›PMID 30105438›Full record

ArticleAnnals of surgical oncology2018

Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma.

Koji Matsuo, Yutaka Takazawa, Malcolm S Ross, Esther Elishaev, Mayu Yunokawa, Todd B Sheridan, Stephen H Bush, Merieme M Klobocista, Erin A Blake, Tadao Takano and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Koji MatsuoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. koji.matsuo@med.usc.edu.
Yutaka TakazawaDepartment of Pathology, Cancer Institute Hospital, Tokyo, Japan.
Malcolm S RossDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA, USA.
Esther ElishaevDepartment of Pathology, MaGee-Womens Hospital, University of Pittsburgh, Pittsburgh, PA, USA.
Mayu YunokawaDepartment of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Todd B SheridanDepartment of Pathology, Mercy Medical Center, Baltimore, MD, USA.
Stephen H BushDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, USA.
Merieme M KlobocistaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Montefiore Medical Center, New York City, NY, USA.
Erin A BlakeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado, Denver, CO, USA.
Tadao TakanoDepartment of Obstetrics and Gynecology, Tohoku University, Miyagi, Japan.
Tsukasa BabaDepartment of Obstetrics and Gynecology, Kyoto University, Kyoto, Japan.
Shinya SatohDepartment of Obstetrics and Gynecology, Tottori University, Tottori, Japan.
Masako ShidaDepartment of Obstetrics and Gynecology, Tokai University, Kanagawa, Japan.
Yuji IkedaDepartment of Obstetrics and Gynecology, The University of Tokyo, Tokyo, Japan.
Sosuke AdachiDepartment of Obstetrics and Gynecology, Niigata University, Niigata, Japan.
Takuhei YokoyamaDepartment of Obstetrics and Gynecology, Osaka Rosai Hospital, Osaka, Japan.
Munetaka TakekumaDepartment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Shiori YanaiDepartment of Obstetrics and Gynecology, Kurashiki Medical Center, Okayama, Japan.
Satoshi TakeuchiDepartment of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan.
Masato NishimuraDepartment of Obstetrics and Gynecology, Tokushima University, Tokushima, Japan.
Keita IwasakiDepartment of Obstetrics and Gynecology, Aichi Medical University, Aichi, Japan.
Marian S JohnsonDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Medical Center, Lexington, KY, USA.
Masayuki YoshidaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Ardeshir HakamDepartment of Pathology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.
Hiroko MachidaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
Paulette Mhawech-FaucegliaDepartment of Pathology, University of Southern California, Los Angeles, CA, USA.
Yutaka UedaDepartment of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
Kiyoshi YoshinoDepartment of Obstetrics and Gynecology, Osaka University, Osaka, Japan.
Hiroshi KajiwaraDepartment of Pathology, Tokai University, Kanagawa, Japan.
Kosei HasegawaDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Masanori YasudaDepartment of Pathology, Saitama Medical University International Medical Center, Saitama, Japan.
Takahito M MiyakeDepartment of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, Japan.
Takuya MoriyaDepartment of Pathology, Kawasaki Medical School, Okayama, Japan.
Yoshiaki YubaDepartment of Pathology, Kitano Hospital, Osaka, Japan.
Terry MorganDepartment of Pathology, Oregon Health and Science University, Portland, OR, USA.
Tomoyuki FukagawaDepartment of Pathology, Iwate Medical University, Morioka, Japan.
Tanja PejovicDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA.
Tadayoshi NaganoDepartment of Obstetrics and Gynecology, Kitano Hospital, Osaka, Japan.
Takeshi SasakiDepartment of Pathology, The University of Tokyo, Tokyo, Japan.
Abby M RichmondDepartment of Pathology, University of Colorado, Denver, CO, USA.
Miriam D PostDepartment of Pathology, University of Colorado, Denver, CO, USA.
Mian M K ShahzadDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, USA.
Dwight D ImDepartment of Gynecology, Mercy Medical Center, Baltimore, MD, USA.
Hiroshi YoshidaDepartment of Pathology, National Cancer Center Hospital, Tokyo, Japan.
Takayuki EnomotoDepartment of Obstetrics and Gynecology, Niigata University, Niigata, Japan.
Kohei OmatsuDepartment of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Frederick R UelandDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Medical Center, Lexington, KY, USA.
Joseph L KelleyDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pittsburgh, Pittsburgh, PA, USA.
Rouzan G KarabakhtsianDepartment of Pathology, University of Kentucky Medical Center, Lexington, KY, USA.
Lynda D RomanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

purposeTo propose a categorization model of uterine carcinosarcoma (UCS) based on tumor cell types (carcinoma and sarcoma) and sarcoma dominance.

methodsThis secondary analysis of a prior multicenter retrospective study examined 889 cases of UCS with available histologic evaluation. Based on survival outcome, cases were clustered into three groups: low-grade carcinoma with nondominant homologous sarcoma [type A, n = 96 (10.8%)], (1) low-grade carcinoma with heterologous sarcoma or any sarcoma dominance and (2) high-grade carcinoma with nondominant homologous sarcoma [type B, n = 412 (46.3%)], and high-grade carcinoma with heterologous sarcoma or any sarcoma dominance [type C, n = 381 (42.9%)]. Tumor characteristics and outcome were examined based on the categorization.

resultsWomen in type C category were more likely to be older, obese, and Caucasian, whereas those in type A category were younger, less obese, Asian, and nulligravid (all P < 0.01). Type C tumors were more likely to have metastatic implants, large tumor size, lymphovascular space invasion with sarcoma cells, and higher lymph node ratio, whereas type A tumors were more likely to be early-stage disease and small (all P < 0.05). On multivariate analysis, tumor categorization was independently associated with progression-free survival (5-year rates: 70.1% for type A, 48.3% for type B, and 35.9% for type C, adjusted P < 0.01) and cause-specific survival (5-year rates: 82.8% for type A, 63.0% for type B, and 47.1% for type C, adjusted P < 0.01).

conclusionCharacteristic differences in clinicopathological factors and outcomes in UCS imply that different underlying etiologies and biological behaviors may be present, supporting a new classification system.

Indexed as

CarcinosarcomaFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedNeoplasm InvasivenessPilot ProjectsPrognosisRetrospective StudiesRisk FactorsSurvival RateUterine Neoplasms

Identifiers

PMID30105438
PMCPMC7521084

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.